UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 2425, 2017

KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.

(Exact name of registrant as specified in its charter)

Japan(State or other jurisdictionof incorporation) 000-55133(CommissionFile Number) 98-1295657 (IRS EmployerIdentification No.)

4-20-3 Ebisu, Shibuya-ku Tokyo, Japan 150-6018 (Address of principal executive offices, including zip code)

+81 3-5789-5872
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company þ

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. þ

Item 15.0107 ~~Entry~~Submission ~~into~~of Matters to a ~~Material~~Vote ~~Definitive~~of ~~Agreement.~~Security Holders

OnThe ~~May~~Ordinary ~~24,~~General ~~2017,~~Meeting aof ~~Sub-Sublease~~Shareholders ~~Agreement~~for (the ~~“Sub-Sublease”)~~Fiscal ~~between~~Year ~~Acucela~~2016 ~~Inc.~~ (~~“Acucela”),~~the a"Annual ~~wholly-owned~~Meeting") ~~subsidiary~~ of Kubota Pharmaceutical Holdings Co., Ltd. (the “"Company”"), ~~and~~was ~~Integrated~~held ~~Diagnostics,~~on ~~Inc.~~May ~~(“Integrated”)~~25, ~~became effective~~2017. ~~The~~At ~~Sub-Sublease~~the ~~relates~~Annual toMeeting, ~~the~~votes ~~sublease~~representing by303,575 ~~Integrated~~units toof ~~Acucela~~shares of ~~approximately~~the ~~8,309~~Company’s ~~square~~common ~~feet~~stock, ofor ~~rentable~~approximately ~~office~~99.5% ~~space~~of ~~located~~the attotal ~~818~~shares ~~Stewart~~entitled ~~Street~~to vote, ~~Suite~~were ~~1100,~~present ~~Seattle,~~and ~~Washington~~voted ~~98101~~to (~~the~~i) ~~“Seattle~~approve ~~Premises”). The~~the ~~effectiveness~~amendment ofto the ~~Sub-Sublease~~Articles ~~and~~of ~~commencement~~Incorporation of ~~its~~the ~~term~~Company ~~was~~to ~~conditioned~~reflect onthe ~~obtaining~~change ~~the~~in ~~consent~~location of the ~~818~~Company’s ~~Stewart~~head ~~Street~~office ~~Acquisition,~~and ~~LLC~~ (~~“Landlord”~~ii) ~~and~~elect ~~Ball~~the ~~Janik,~~five ~~LLP~~nominees ~~(“Ball~~to ~~Janik”)~~the Board of Directors. The ~~term~~proposals ofrelated to each matter are described in detail in the ~~Sub-Sublease~~Company’s ~~expires~~definitive proxy statement on ~~October~~Schedule ~~29,~~14A ~~2020~~filed (with the ~~“Sub-Sublease~~Securities ~~Term”)~~and Exchange Commission on April 27, 2017. The voting results for each proposal are as follows:

~~Monthly base rent under the Sub-Sublease is approximately $12,290~~1.40 ~~for~~To ~~the~~approve ~~first year of~~ the ~~term,~~amendment ~~subject~~ to ~~increases~~the ofArticles ~~approximately 5% annually on May 1st~~ of ~~each~~Incorporation ~~year~~ of the ~~Sub-Sublease~~Company ~~Term. No rent is payable for the first two months of the Sub-Sublease Term. In addition~~ to ~~the~~reflect ~~base rent, Acucela is responsible for its pro rata share of building operating expenses, calculated with reference to~~ the ~~rentable~~change ~~square~~in ~~feet~~location of the ~~Seattle~~Company’s ~~Premises.~~head office:

The Sub-Sublease is subject and subordinate to Integrated’s sublease of the Seattle Premises pursuant to its Sublease Agreement with Ball Janik, dated November 20, 2014 (the “Sublease”) and Ball Janik’s lease of the Seattle Premises pursuant to its Office Lease with Landlord, dated July 19, 2010 (the “Master Lease”). The Sub-Sublease contains customary default provisions allowing Integrated to terminate the Sub-Sublease if Acucela fails to cure a breach of any of its obligations within specified time periods. Acucela may not assign the Sub-Sublease or further sublet all or any part of the Seattle Premises without prior written consent from Integrated, Ball Janik and Landlord.



Votes For	Votes Against	Abstentions	Broker Non-Votes
302,900	671	—	—

A2. ~~copy~~To ofelect the ~~Sub-Sublease is~~five ~~filed~~nominees ~~as Exhibit 10.1~~ to ~~this~~the ~~report~~Board ~~and incorporated herein by reference. The foregoing description~~ of ~~the~~Directors, ~~terms~~each ~~and~~to ~~conditions~~serve ofa ~~the Sub~~one-~~Sublease is~~year ~~qualified in its entirety by reference to such exhibit.~~term

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.



Nominee	Votes For	Votes Against	Abstentions	Broker Non-Votes
Shintaro Asako	302,475	926	—	—
Ryo Kubota, M.D., Ph.D.	302,540	861	—	—
Shiro Mita	302,528	873	—	—
Eisaku Nakamura	302,512	889	—	—
Robert Takeuchi	302,500	901	—	—

~~The information set forth and referenced under~~ Item 18.01 isOther ~~hereby incorporated by reference into this Item 2~~Events.~~03.~~

Item 9.01	Financial Statements and Exhibits
(d) Exhibits.
Exhibit Number		Description
10.1		Sub-Sublease Agreement by and between Integrated Diagnostics, Inc. and Acucela Inc.

On May 26, 2017, the Company filed an extraordinary report with the Financial Services Agency of Japan reporting the results of the Annual Meeting. An English translation of the extraordinary report is filed as Exhibit 99.1 to this Current Report on Form 8-K.



Item 9.01	Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number		Description
99.1		Extraordinary report dated May 26, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.		~~KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.~~
Date: May 25, 2017
Date: May 26, 2017
	By:	/s/ John E. Gebhart
		John E. Gebhart
		Chief Financial Officer

EXHIBIT INDEX

Exhibit Number		Description
10.1		Sub-Sublease Agreement by and between Integrated Diagnostics, Inc. and Acucela Inc.
99.1		Extraordinary report dated May 26, 2017.

Filing Compare · KUBOTA PHARMACEUTICAL HOLDINGS CO LTD